Literature DB >> 2509867

Tissue doses from radiotherapy of cancer of the uterine cervix.

M Stovall1, S A Smith, M Rosenstein.   

Abstract

For use in an epidemiologic study of subsequent tumors, absorbed doses from brachytherapy and external beam radiotherapy were measured and calculated for various tissues of patients treated for cancer of the uterine cervix. External beams included orthovoltage x rays (1.9 and 3.0 mm Cu half-value layer), cobalt-60 gamma rays, 2 MV x rays, and 25 MV X rays. The brachytherapy sources were encapsulated radium. Measurements were made in an Alderson anthropomorphic phantom and a water phantom; calculations were made using a Monte Carlo technique or standard radiotherapy methods. Depending upon stage of disease and radiation energy, the absorbed doses (cGy) from typical treatment regimes to tissues of interest were: ovaries, 1400-5200; stomach, 130-320; kidneys, 120-310; pancreas, 100-260; lungs 22-48; breasts, 19-52; thyroid, 6-17; salivary glands, 4-11; brain, 2-7, and total active bone marrow, 320-1100. The lower values of each range were for stage I of the disease.

Entities:  

Mesh:

Year:  1989        PMID: 2509867     DOI: 10.1118/1.596331

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  11 in total

1.  Methodology for determining doses to in-field, out-of-field and partially in-field organs for late effects studies in photon radiotherapy.

Authors:  Rebecca M Howell; Sarah B Scarboro; Phillip J Taddei; Sunil Krishnan; Stephen F Kry; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  Epidemiological designs in radioepidemiological research.

Authors:  E Cardis; J Estève
Journal:  Soz Praventivmed       Date:  1991

Review 3.  An exponential growth of computational phantom research in radiation protection, imaging, and radiotherapy: a review of the fifty-year history.

Authors:  X George Xu
Journal:  Phys Med Biol       Date:  2014-08-21       Impact factor: 3.609

4.  Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.

Authors:  M M Hawkins; L M Wilson; M A Stovall; H B Marsden; M H Potok; J E Kingston; J M Chessells
Journal:  BMJ       Date:  1992-04-11

5.  Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study.

Authors:  Parveen Bhatti; Lene H S Veiga; Cécile M Ronckers; Alice J Sigurdson; Marilyn Stovall; Susan A Smith; Rita Weathers; Wendy Leisenring; Ann C Mertens; Sue Hammond; Debra L Friedman; Joseph P Neglia; Anna T Meadows; Sarah S Donaldson; Charles A Sklar; Leslie L Robison; Peter D Inskip
Journal:  Radiat Res       Date:  2010-10-06       Impact factor: 2.841

6.  Adaptations to a Generalized Radiation Dose Reconstruction Methodology for Use in Epidemiologic Studies: An Update from the MD Anderson Late Effect Group.

Authors:  Rebecca M Howell; Susan A Smith; Rita E Weathers; Stephen F Kry; Marilyn Stovall
Journal:  Radiat Res       Date:  2019-06-18       Impact factor: 2.841

Review 7.  A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction.

Authors:  X George Xu; Bryan Bednarz; Harald Paganetti
Journal:  Phys Med Biol       Date:  2008-06-09       Impact factor: 3.609

8.  Second primary malignancies following gynecological tumours in Saarland, Germany, 1968-1987.

Authors:  H Brenner; S Siegle; C Stegmaier; H Ziegler
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Assessment of organ-specific neutron equivalent doses in proton therapy using computational whole-body age-dependent voxel phantoms.

Authors:  Christina Zacharatou Jarlskog; Choonik Lee; Wesley E Bolch; X George Xu; Harald Paganetti
Journal:  Phys Med Biol       Date:  2008-01-10       Impact factor: 3.609

10.  Risk of colorectal cancer among long-term cervical cancer survivors.

Authors:  Ana M Rodriguez; Yong-Fang Kuo; James S Goodwin
Journal:  Med Oncol       Date:  2014-04-03       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.